MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

The city needs a new sports stadium for student athletes, but that can be done for about $20 million. Imagine what could be ...

New Iowa laws on issues from transgender civil rights protections to changes to Iowa’s unemployment insurance tax system will ...

The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...

We've tried to do everything we can for him, but nothing changes for long and the cycle starts all over again.

After 35 years, the Pediatric Interim Care Center in Kent – the only specialized medical facility in western Washington ...

General Food Labeling Requirements and Labeling-Related Sample Analysis — Domestic and Import” replaces the previous 2010 ...

The FDA's breakthrough devices program helps the industry with faster review times, but the benefit to patients is unclear.

The FDA’s clunky launch of Elsa, an AI tool to increase efficiency, has sparked concern from agency employees and outside ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said ...

The Advocate highlights social inequality through original stories and opinions, and content generated by fellow NNPA and other publications ...

Curay, the top FDA drug regulator, acknowledged that much is still in flux at the agency and introduced a new deputy.